Selective HDAC IIa inhibition was identified as a viable alternative approach to avoid the potential adverse effects of broad spectrum HDAC inhibition in pulmonary arterial hypertension.
MicroRNAs (miRs) 424 and 503 are effective in human and animal models of pulmonary arterial hypertension and may be the basis for effective therapeutics.
OCR5753 is the most potent anti-HIV agent with activity towards wild-type HIV-1. OCR5753 is 10 times more potent than any NNRTI reported to date.
A small-molecule named “antibody-recruiting molecule targeting HIV-1 (analog 3)” (ARM-H-3) targeted for the treatment of HIV (240nM HIV antagonist).
OCR 5557 offers neutralizing monoclonal and rabbit polyclonal antibodies that are not cross-reactive with macrophage migration inhibitory factor (MIF).
Animal-free product that avoids pathogen or immunogenic contamination of animal products.
Neutralizing antibodies to OCR6325 are potential immune therapeutic agents to treat cancers that overexpress a novel soluble target expressed in epithelia.
Beta.-peptide regions of polypeptides can serve as structural mimics of .alpha.-helices in wild type proteins. Because .alpha.-helices of one protein often bind to a target protein in a biological pathway, a polypeptide that contains a helical .beta.-peptide region can be used to disrupt this type of protein-protein binding. As a result, polypeptides that contain a helical .beta.-peptide region can be used to treat conditions involving this type of protein-protein binding, such as viral infections and cell proliferation.